Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-06-05
2010-12-28
Bunner, Bridget E (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S345000, C530S350000, C530S402000, C514S012200
Reexamination Certificate
active
07858739
ABSTRACT:
The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
REFERENCES:
patent: 5235041 (1993-08-01), Cappello et al.
patent: 5514581 (1996-05-01), Ferrari et al.
patent: 5545620 (1996-08-01), Wahl et al.
patent: 5641648 (1997-06-01), Ferrari et al.
patent: 5770697 (1998-06-01), Ferrari et al.
patent: 5792742 (1998-08-01), Gold et al.
patent: 6018030 (2000-01-01), Ferrari et al.
patent: 6207446 (2001-03-01), Szostak et al.
patent: 6214553 (2001-04-01), Szostak et al.
patent: 6258558 (2001-07-01), Szostak et al.
patent: 6261804 (2001-07-01), Szostak et al.
patent: 6281344 (2001-08-01), Szostak et al.
patent: 6383775 (2002-05-01), Duff et al.
patent: 6462189 (2002-10-01), Koide
patent: 6518018 (2003-02-01), Szostak et al.
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 6559126 (2003-05-01), Tournaire et al.
patent: 6660492 (2003-12-01), Bode et al.
patent: 6818418 (2004-11-01), Lipovsek et al.
patent: 7115396 (2006-10-01), Lipovsek et al.
patent: 2002/0019517 (2002-02-01), Koide
patent: 2002/0061307 (2002-05-01), Whitlow et al.
patent: 2003/0104520 (2003-06-01), Ellington et al.
patent: 2003/0170753 (2003-09-01), Koide
patent: 2005/0255548 (2005-11-01), Lipovsek et al.
patent: 04-108827 (1992-04-01), None
patent: WO-98/12226 (1998-03-01), None
patent: WO-98/31700 (1998-07-01), None
patent: WO-98/56915 (1998-12-01), None
patent: WO-99/51773 (1999-10-01), None
patent: WO-00/34784 (2000-06-01), None
patent: WO-01/64942 (2001-09-01), None
patent: WO-02/04523 (2002-01-01), None
patent: WO-02/32925 (2002-04-01), None
patent: WO-03/022858 (2003-03-01), None
patent: WO 03/075840 (2003-09-01), None
patent: WO-2008/097497 (2008-08-01), None
patent: WO-2009/025806 (2009-02-01), None
patent: WO-2009/073115 (2009-06-01), None
Main et al, 1993. Cell 71: 671-678.
Matsushima et al, 1980. Chemistry Letters, p. 773-776.
Posey et al (May 2002, slides from presentation at 2002 American Society of Clinical Oncology (ASCO) Annual Meeting, May 18-21).
Caliceti, P., et al., “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)—protein conjugates,”Advanced Drug Delivery Reviews, 55:1261-1277 (2003).
Masabumi Shibuya, “Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E,”Cancer Sci., 94(9):751-756 (2003).
Bork et al., Go Hunting In Sequence Databases But Watch Out for the Traps,Trends in Genetics12:10, 425-427 (1996).
Bork P., Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,Genome Research10, 398-400 (2000).
Brenner S.E., Errors in Genome Annotation,Trends in Genetics15:4, 132-133 (1999).
Choy et al., Efficacy of a Novel PEGylated Humanized Anti-TNF Fragment (CDP870) in Patients with Rheumatoid Arthritis: a Phase II Double-Blinded, Randomized, Dose-Escalating Trial,Rheumatology41, 1133-1137 (2002).
Doerks et al., Protein Annotation: Detective Work for Function Prediction,Trends in Genetics14:6, 248-250 (1998).
Skolnick et al., From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,Trends in Biotech.18:1, 34-39 (2000).
Smith et al., The Challenges of Genome Sequence Annotation or “The Devil is in the Details”,Nature Biotechnology15, 1222-1223 (1997).
Maeda H., SMANCS and Polymer-Conjugated Macromolecular Drugs: Advantages in Cancer Chemotherapy,Advanced Drug Delivery Reviews, 46: 169-185 (2001).
Muyldermans S., Single Domain Camel Antibodies: Current Status,Reviews in Molecular Biotechnology, 74: 277-302, (2001).
Yang et al., Tailoring Structure-Function and Pharmacokinetic Properties of Single-Chain Fv Proteins by Site-Specific PEGylation, 16:(10) 761-770, (2003).
Zdanov, A., et al., Structure Of A Single-Chain Antibody Variable Domain (Fv) Fragment Complexed With a Carbohydrate Antigen At 1.7-A Resolution,PNAS, 91:6423-6427 (1994).
Muyldermans “Single domain camel antibodies: current status.” Reviews in Molecular Biolgoy 74: 277-302 (2001).
Maeda et al., “SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.” Advanced Drug Delivery Reviews. 46: 169-185 (2001).
Yang et al., “Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation” Protein Engineering. 16(10): 761-770 (2003).
Boder, et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,” PNAS, vol. 97(20), pp. 10701-10705 (2000).
Kohler and Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature, vol. 256, pp. 495-497 (1975).
Markland et al., “Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display”, 2. Plasma Kallikrein and Thrombin. Biochemistry, vol. 35, pp. 8058-8067 (1996).
Parker et al., “Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two”, Protein Engineering, Design & Selection, vol. 18(9), pp. 435-444 (2005).
Tang, L. et al., “Pharmacokinetic aspects of biotechnology products”, J. Pharm Sci., vol. 93, pp. 2184-2204 (2004).
Apte et al., Anchor-Ligated cDNA Libraries: A Technique for Generating a cDNA Library for the Immediate Cloning of the 5′ Ends of mRNAs.Biotechniques15, 890-893 (1993).
Bae et al., Arginine-Rich Anti-Vascular Endothelial Growth Factor Peptides Inhibit Tumor Growth and Metastasis by Blocking Angiogenesis,J. Biol. Chem., 275:13588 (2000).
Baggio et al., Identification of epitope-like consensus motifs using mRNA display,J. Mol. Recognit., 15: 126-134 (2002).
Baron et al., Protein Modules,Elsevier Science Publishers Ltd.. (UK) , 13-17 (1991).
Baron et al., H NMR Assignment and Secondary Structure of the Cell Adhesion Type III Module of Fibronectin.Biochemistry31, 2068-2073 (1992).
Batori et al.,Protein Eng., Exploring the Potential of the Monobody Scaffold: Effects of Loop Elongation on the Stability of a Fibronectin Type III Domain, 15(12):1015-1020 (2002).
Bianchi et al., High Level Expression and Rational Mutagenesis of a Designed Protein, the Minibody.J. Mol. Biol.236, 649-659 (1994).
Boder et al., Yeast Surface Display for Screening Combinatorial Polypeptide Libraries.Nat. Biotech.15, 553-557 (1997).
Boldicke et al., Anti-VEGFR-2 scFvs for Cell Isolation. Single-Chain Antibodies Recognizing the Human Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2/flk-1) on the Surface of Primary Endothelial Cells and Preselected CD34+Cells from Cord Blood.,Stem Cells, 19(1):24-36 (2001).
Bork and Doolittle, Proposed Acquisition of an Animal Protein Domain by Bacteria.PNAS89, 8990-94 (1992).
Bork et al., The Immunoglobulin Fold Structural Classification, Sequence Patterns and Common Core,J. Mol. Biol., 242(4):309-320 (1994).
Brock, K. et al., Nucleotide sequencing of 5′ and 3′ termini of bovine viral diarrhea virus by RNA ligation and PCR,J. Virol. Methods38, 39-46 (1992).
Bruzik, J. et al., “Spliced leader RNAs from lower eukaryotes are trans-spliced in mammalian cells,”Nature360, 692-695 (1992).
Campbell & Spitzfaden, Building Proteins with Fibronectin Type III Modules,Structure, 2(5):333-337 (1994).
Clackson and Wells, In Vitro Selection from Protein and Peptide Libraries.TIB TECH12, 173-184 (1994).
Clackson et al., Making Antibody Fragments Using Phage Display Libraries.Nature352, 624-628 (1991).
Claffey et al., Vascular Endothelial Growth Factor,J. Biol. Chem., 267:16317-16322 (1992).
Clarke et al., Folding and Stability of a Fibronectin Type III Domain of Human Tenascin.J. Mol. Biol.270, 771-778 (1997).
Copie et al., Solution Structure and Dynamics of Linked Cell Attachment Modules of Mouse F
Chen Yan
Getmanova Elena
Gokemeijer Jochem
Harris Alan S.
Lim Ai Ching
Bristol--Myers Squibb Company
Bunner Bridget E
Howard Zachary C
Ropes & Gray LLP
LandOfFree
Inhibitors of type 2 vascular endothelial growth factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of type 2 vascular endothelial growth factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of type 2 vascular endothelial growth factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175817